Wilson Sonsini Advises RA Capital Management on Rivus Pharmaceuticals’ $132 Million Series B
- Client Highlights
- Life Sciences
On September 22, 2022, Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG, and existing investors Longitude Capital, Medicxi, and RxCapital. Wilson Sonsini Goodrich & Rosati advised RA Capital in the transaction.
Funds from the Series B will primarily be used to further support clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease.
The Wilson Sonsini team that advised RA Capital on the transaction includes:
For more information, please see Rivus Pharmaceuticals' news release.